MYOS Executive Chairman Robert Hariri, MD, PhD Responds to WSJ Article: “Drugs Aim to Help Elderly Rebuild Muscle”

The Wall Street Journal this morning released an article touting the significant developments being made in the field of myostatin inhibitors and muscle health research. MYOS Corporation, a bionutrition and biotherapeutics company, is a key player in the field of muscle health. In addition to focusing on the development and commercialization of products that improve the muscle function essential to managing sarcopenia, they are also improving the quality and longevity of those who battle cachexia and muscle loss related to chronic illness such as cancer, diabetes, heart disease, rheumatoid arthritis, and other chronic pain diseases.

Earlier today, MYOS Founder Dr. Robert Hariri commented on the article:

"We are happy to share the recent report from the Wall Street Journal entitled 'Drugs Aim to Help Elderly Rebuild Muscle,' which emphasizes the growing interest in myostatin inhibition as an important target for the treatment of age- and disease-related muscle loss. As is clear from this report, the level of attention directed at the development of pharmaceutical and biologic agents, which can modulate myostatin activity by the biopharmaceutical industry, validates the ongoing work at MYOS Corporation and specifically highlights the enormous value of the natural myostatin inhibitor, FortetropinTM (also known as MYO-T12®). Unlike products in development, which face a potential of five to 10 years in the regulatory process, our products are available today. We feel that MYOS products fill an important need today and will continue to be important well into the future."

To learn more about the groundbreaking biotherapeutic and bionutritional research being done by MYOS, visit